Singapore allocates S$350m to longevity research; Alzchem confronts creatine supply crunch
Singapore's government commits S$350 million to healthy longevity research, focusing on brain and physical function. Concurrently, Alzchem Group reports a global tripling of creatine demand, forcing a €120 million capacity expansion.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Singapore, a key market for premium nutraceuticals, has announced a significant investment into healthy longevity research. The government is allocating S$350 million (US$273 million) towards the Grand Challenge on Maximising Healthy and Successful Longevity, an initiative under the broader Research, Innovation and Enterprise 2030 (RIE 2030) framework. Minister for Health Ong Ye Kung confirmed the funding, which will specifically target research into brain health and physical function, alongside socio-environmental innovations. This investment underscores Singapore's strategic focus on healthy ageing as both an economic and societal priority, creating a robust framework for scientific validation of longevity-focused ingredients and finished products.
In the ingredient sector, German manufacturer Alzchem Group is struggling to meet unprecedented demand for creatine. Robert Alber, Vice President of Human Nutrition, reported that global demand for creatine has tripled in the past two years, moving beyond its traditional sports nutrition niche into women's health, cognitive function, and healthy ageing applications. Alzchem, the primary non-Asian supplier of creatine monohydrate, particularly its high-purity Creapure brand, is experiencing severe capacity pressures. To address this, the company is investing €120 million in a new German production facility, but this expansion will not be operational until late 2027, indicating sustained supply constraints for the next 18-24 months.
The surge in demand highlights a significant market shift, where the broader public is increasingly adopting ingredients previously confined to specialised consumer segments. Alzchem's unique position as the sole Western manufacturer of pure creatine monohydrate means its supply challenges disproportionately affect brands prioritising ingredient quality and supply chain transparency. Ongoing supply tightness will likely lead to higher input costs and extended lead times for brand owners reliant on high-grade creatine, necessitating strategic inventory management and potential reformulation considerations.
What this means for Singapore
Singaporean brand owners and manufacturers are presented with a unique opportunity to align product development with national research priorities. The S$350 million government investment into healthy longevity research, particularly in brain health and physical function, creates a fertile ground for collaboration and co-funding. Brands focusing on scientifically validated ingredients for these areas could gain a competitive edge and direct access to research findings by partnering with local institutions. However, the premium market in Singapore will also be affected by global creatine supply shortages. Brand owners may need to diversify sourcing or manage consumer expectations regarding price increases and potential stockouts for creatine-containing products until Alzchem's new facility comes online in late 2027.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.